FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001446148> ?p ?o ?g. }

• W2001446148 endingPage "522" @default.
• W2001446148 startingPage "522" @default.
• W2001446148 abstract "<h3>Abstract</h3> <b>Objective:</b> To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. <b>Design:</b> Modelling cost effectiveness. <b>Setting:</b> UK NHS. <b>Participants:</b> Patients with relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis. <b>Main outcome measures:</b> Cost per quality adjusted life year gained. <b>Results:</b> The base case cost per quality adjusted life year gained by using any of the four treatments ranged from £42 000 ($66 469; €61 630) to £98 000 based on efficacy information in the public domain. Uncertainty analysis suggests that the probability of any of these treatments having a cost effectiveness better than £20 000 at 20 years is below 20%. The key determinants of cost effectiveness were the time horizon, the progression of patients after stopping treatment, differential discount rates, and the price of the treatments. <b>Conclusions:</b> Cost effectiveness varied markedly between the interventions. Uncertainty around point estimates was substantial. This uncertainty could be reduced by conducting research on the true magnitude of the effect of these drugs, the progression of patients after stopping treatment, the costs of care, and the quality of life of the patients. Price was the key modifiable determinant of the cost effectiveness of these treatments. <h3>What is already known on this topic</h3> Interferon beta and glatiramer acetate are the only disease modifying therapies used to treat multiple sclerosis Economic evaluations of these drugs have had flaws in the specification of the course of the disease, efficacy, duration of treatment, mortality, and the analysis of uncertainty None of the existing estimates of cost effectiveness can be viewed as robust <h3>What this study adds</h3> The cost per quality adjusted life year gained is unlikely to be less than £40 000 for interferon beta or glatiramer acetate Experience after stopping treatment is a key determinant of the cost effectiveness of these therapies Key factors affecting point estimates of cost effectiveness are the cost of interferon beta and glatiramer acetate, the effect of these therapies on disease progression, and the time horizon evaluated" @default.
• W2001446148 created "2016-06-24" @default.
• W2001446148 creator A5004828576 @default.
• W2001446148 creator A5028509069 @default.
• W2001446148 creator A5052408374 @default.
• W2001446148 creator A5061681421 @default.
• W2001446148 creator A5064431176 @default.
• W2001446148 creator A5078022391 @default.
• W2001446148 creator A5083168810 @default.
• W2001446148 creator A5086081444 @default.
• W2001446148 date "2003-03-08" @default.
• W2001446148 modified "2023-10-18" @default.
• W2001446148 title "Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis * Commentary: Evaluating disease modifying treatments in multiple sclerosis" @default.
• W2001446148 cites W1545382406 @default.
• W2001446148 cites W1974859486 @default.
• W2001446148 cites W1980187445 @default.
• W2001446148 cites W2000665481 @default.
• W2001446148 cites W2005506388 @default.
• W2001446148 cites W2008120870 @default.
• W2001446148 cites W2010121852 @default.
• W2001446148 cites W2030592068 @default.
• W2001446148 cites W2069745333 @default.
• W2001446148 cites W2097669496 @default.
• W2001446148 cites W2111403822 @default.
• W2001446148 cites W2112165124 @default.
• W2001446148 cites W2134342836 @default.
• W2001446148 cites W2139367012 @default.
• W2001446148 cites W2145185401 @default.
• W2001446148 cites W2169098250 @default.
• W2001446148 cites W2432640161 @default.
• W2001446148 cites W2983782887 @default.
• W2001446148 doi "https://doi.org/10.1136/bmj.326.7388.522" @default.
• W2001446148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/150460" @default.
• W2001446148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12623909" @default.
• W2001446148 hasPublicationYear "2003" @default.
• W2001446148 type Work @default.
• W2001446148 sameAs 2001446148 @default.
• W2001446148 citedByCount "125" @default.
• W2001446148 countsByYear W20014461482012 @default.
• W2001446148 countsByYear W20014461482013 @default.
• W2001446148 countsByYear W20014461482014 @default.
• W2001446148 countsByYear W20014461482015 @default.
• W2001446148 countsByYear W20014461482016 @default.
• W2001446148 countsByYear W20014461482017 @default.
• W2001446148 countsByYear W20014461482018 @default.
• W2001446148 countsByYear W20014461482019 @default.
• W2001446148 countsByYear W20014461482020 @default.
• W2001446148 countsByYear W20014461482021 @default.
• W2001446148 countsByYear W20014461482022 @default.
• W2001446148 countsByYear W20014461482023 @default.
• W2001446148 crossrefType "journal-article" @default.
• W2001446148 hasAuthorship W2001446148A5004828576 @default.
• W2001446148 hasAuthorship W2001446148A5028509069 @default.
• W2001446148 hasAuthorship W2001446148A5052408374 @default.
• W2001446148 hasAuthorship W2001446148A5061681421 @default.
• W2001446148 hasAuthorship W2001446148A5064431176 @default.
• W2001446148 hasAuthorship W2001446148A5078022391 @default.
• W2001446148 hasAuthorship W2001446148A5083168810 @default.
• W2001446148 hasAuthorship W2001446148A5086081444 @default.
• W2001446148 hasBestOaLocation W20014461481 @default.
• W2001446148 hasConcept C112930515 @default.
• W2001446148 hasConcept C126322002 @default.
• W2001446148 hasConcept C159110408 @default.
• W2001446148 hasConcept C177713679 @default.
• W2001446148 hasConcept C1862650 @default.
• W2001446148 hasConcept C203014093 @default.
• W2001446148 hasConcept C2778577042 @default.
• W2001446148 hasConcept C2779134260 @default.
• W2001446148 hasConcept C2779951463 @default.
• W2001446148 hasConcept C2780640218 @default.
• W2001446148 hasConcept C2994247566 @default.
• W2001446148 hasConcept C3019080777 @default.
• W2001446148 hasConcept C64332521 @default.
• W2001446148 hasConcept C71924100 @default.
• W2001446148 hasConceptScore W2001446148C112930515 @default.
• W2001446148 hasConceptScore W2001446148C126322002 @default.
• W2001446148 hasConceptScore W2001446148C159110408 @default.
• W2001446148 hasConceptScore W2001446148C177713679 @default.
• W2001446148 hasConceptScore W2001446148C1862650 @default.
• W2001446148 hasConceptScore W2001446148C203014093 @default.
• W2001446148 hasConceptScore W2001446148C2778577042 @default.
• W2001446148 hasConceptScore W2001446148C2779134260 @default.
• W2001446148 hasConceptScore W2001446148C2779951463 @default.
• W2001446148 hasConceptScore W2001446148C2780640218 @default.
• W2001446148 hasConceptScore W2001446148C2994247566 @default.
• W2001446148 hasConceptScore W2001446148C3019080777 @default.
• W2001446148 hasConceptScore W2001446148C64332521 @default.
• W2001446148 hasConceptScore W2001446148C71924100 @default.
• W2001446148 hasIssue "7388" @default.
• W2001446148 hasLocation W20014461481 @default.
• W2001446148 hasLocation W20014461482 @default.
• W2001446148 hasLocation W20014461483 @default.
• W2001446148 hasLocation W20014461484 @default.
• W2001446148 hasLocation W20014461485 @default.
• W2001446148 hasOpenAccess W2001446148 @default.
• W2001446148 hasPrimaryLocation W20014461481 @default.
• W2001446148 hasRelatedWork W1973644616 @default.
• W2001446148 hasRelatedWork W2004358167 @default.

• next